Thirty years of hemophilia treatment in the Netherlands, 1972-2001

被引:95
作者
Plug, I
van der Bom, JG
Peters, M
Mauser-Bunschoten, EP
de Goede-Bolder, A
Heijnen, L
Smit, C
Rijkom, JEFZV
Willemse, J
Rosendaal, FR
机构
[1] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands
[2] Ctr Hemostasis & Thrombosis Res, NL-2300 RC Leiden, Netherlands
[3] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands
[4] Univ Utrecht, Med Ctr, Utrecht, Netherlands
[5] Rehabilit Ctr De Trappenberg, Huizen, Netherlands
[6] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Rotterdam, Netherlands
[7] Hosp Pharm Noordoost Brabant, sHertogenbosch, Netherlands
[8] Netherlands Hemophilia Soc, Badhoevedorp, Netherlands
关键词
D O I
10.1182/blood-2004-05-2008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the introduction of replacement therapy in the early 1960S by the infusion of plasma-derived factor VIII and IX preparations, important changes have occurred for hemophilia patients. We studied the medical and social developments over 30 years of hemophilia treatment. Since 1972, 5 cross-sectional national postal surveys among all hemophilia patients in the Netherlands were performed, the latest in 2001. The prestructured questionnaires included items on treatment, the presence of inhibitory antibodies against factor VIII or IX, the annual number of bleeding episodes, use of inpatient hospital care, and hepatitis C and HIV infections. Response rate in 2001 was 70%. Young patients (<16 years) with severe hemophilia showed the largest increase in use of prophylaxis, from 34% in 1972 to 86% in 2001. The occurrence of hemorrhages has gradually decreased. Hospital admissions decreased from 47% of all patients in 1972 to 18% in 2001. Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:3494 / 3500
页数:7
相关论文
共 25 条
[1]  
AHLBERG A, 1965, ACTA ORTHOP SCAND S, P132
[2]   When to start and when to stop primary prophylaxis in patients with severe haemophilia [J].
Astermark, J .
HAEMOPHILIA, 2003, 9 :32-36
[3]   Consensus perspectives on prophylactic therapy for haemophilia:: summary statement [J].
Berntorp, E ;
Astermark, J ;
Björkman, S ;
Blanchette, VS ;
Fischer, K ;
Giangrande, PLF ;
Gringeri, A ;
Ljung, RC ;
Manco-Johnson, MJ ;
Morfini, M ;
Kilcoyne, RF ;
Petrini, P ;
Rodriguez-Merchan, EC ;
Schramm, W ;
Shapiro, A ;
Van Den Berg, HM ;
Hart, C .
HAEMOPHILIA, 2003, 9 :1-4
[4]  
*CENTR BUR STAT NE, 2003, STAT LIN DAT
[5]   PROPHYLAXIS OF JOINT HEMORRHAGES IN HEMOPHILIA [J].
CREVELD, SV .
ACTA HAEMATOLOGICA, 1971, 45 (02) :120-+
[6]   Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy [J].
Fischer, K ;
Van der Bom, JG ;
Mauser-Bunschoten, EP ;
Roosendaal, G ;
Prejs, R ;
Grobbee, DE ;
Van den Berg, HM .
HAEMOPHILIA, 2001, 7 (05) :446-452
[7]   Prospective controlled studies on prophylaxis: an Italian approach [J].
Gringeri, A .
HAEMOPHILIA, 2003, 9 :38-42
[8]   LIFE EXPECTANCY OF SWEDISH HEMOPHILIACS, 1831-1980 [J].
LARSSON, SA .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 59 (04) :593-602
[9]   North American prophylaxis studies for persons with severe haemophilia: background, rationale and design [J].
Manco-Johnson, MJ ;
Blanchette, VS .
HAEMOPHILIA, 2003, 9 :44-48